GRACE :: Lung Cancer

progression

Denise Brock

ASCO 2017 – Lung Cancer – Continuing Immunotherapy Beyond Progression

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss Continuing Immunotherapy Beyond Progression.



 

 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


GRACE Video

Understanding Acquired Resistance in ALK+ Lung Cancer

Share

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments – and why some do better than expected. February 2014


GRACE Video

Treating Brain Mets in ALK+ Lung Cancer

Share

For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014


GRACE Video

ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori

Share

New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the “Download” button above. Get the latest QuickTime Player.)


GRACE Video

ALK Positive Lung Cancer Forum 2014: Xalkori

Share

Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval, as well as the limitations and side effects of the drug.

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the “Download” button above. Get the latest QuickTime Player.)


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243